Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Targeted therapies for cardiac diseases

Nature Reviews Cardiology volume 19, pages 343–344 (2022)Cite this article

Subjects

Heart failure is a systemic disease in which neuroendocrine activation, inflammation and metabolic changes can impair cardiac function. In addition, variants in genes encoding sarcomeric proteins can predispose individuals to develop heart failure. The 2022 Gordon Research Conference on Cardiac Regulatory Mechanisms aims to identify novel treatment targets by applying high-resolution approaches to complex cardiac disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Established and potential novel targets in heart failure.

References

  1. Lehman, S. J., Crocini, C. & Leinwand, L. A. Targeting the sarcomere in inherited cardiomyopathies. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00682-0 (2022).

    Article  PubMed  Google Scholar 

  2. Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351–356 (2019).

    Article  CAS  Google Scholar 

  3. Robertson, J. et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation 140, 117–125 (2019).

    Article  CAS  Google Scholar 

  4. Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761–772 (2020).

    Article  CAS  Google Scholar 

  5. Paulus, W. J. & Zile, M. R. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ. Res. 128, 1451–1467 (2021).

    Article  CAS  Google Scholar 

  6. Wong, A., Hamidzada, H. & Epelman, S. A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00701-0 (2022).

    Article  PubMed  Google Scholar 

  7. Carnevale, D. Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00678-w (2022).

    Article  PubMed  Google Scholar 

  8. Caporizzo, M. A. & Prosser, B. L. The microtubule cytoskeleton in cardiac mechanics and heart failure. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00692-y (2022).

    Article  PubMed  Google Scholar 

  9. Karlstaedt, A., Moslehi, J. & de Boer, R. A. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00698-6 (2022).

    Article  PubMed  Google Scholar 

  10. Meijers, W. C. et al. Heart failure stimulates tumor growth by circulating factors. Circulation 138, 678–691 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

C.M. is funded by the German Research Foundation (DFG; Ma 2528/7-1; SFB 894, SFB 1525), the Barth Syndrome Foundation and the Corona Foundation. J.C.T. is funded by the NIH (HL075619, HL107046 and 137375) and the Steven M. Gootter Foundation.

Author information

Authors and Affiliations

  1. Department for Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany

    Christoph Maack

  2. Medical Clinic I, University Clinic Würzburg, Würzburg, Germany

    Christoph Maack

  3. Departments of Biomedical Engineering and Medicine, University of Arizona, Tucson, AZ, USA

    Jil C. Tardiff

Authors
  1. Christoph Maack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jil C. Tardiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Maack.

Ethics declarations

Competing interests

C.M. received honoraria as a speaker or consultant from Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pfizer and Servier. J.C.T. received honoraria as a speaker or consultant from Bristol Myers Squibb, Cytokenetics and MyoKardia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maack, C., Tardiff, J.C. Targeted therapies for cardiac diseases. Nat Rev Cardiol 19, 343–344 (2022). https://doi.org/10.1038/s41569-022-00704-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-022-00704-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing